Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 20160505)

1.

Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q.

Starczynowski DT, Karsan A.

Cell Cycle. 2010 Mar 1;9(5):855-6. Epub 2010 Mar 11. No abstract available.

2.

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL.

Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.

3.

[Ribosomal protein in impaired erythropoiesis: Diamond-Blackfan anemia and 5q- syndrome].

Ito E.

Rinsho Ketsueki. 2009 Oct;50(10):1539-47. Review. Japanese. No abstract available.

PMID:
19915364
4.

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.

Pellagatti A, Hellström-Lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Fidler C, Cazzola M, Wainscoat JS, Boultwood J.

Br J Haematol. 2008 Jul;142(1):57-64. doi: 10.1111/j.1365-2141.2008.07178.x. Epub 2008 May 8. Erratum in: Br J Haematol. 2009 Feb;144(3):455.

5.

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.

Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F.

Haematologica. 2008 Jul;93(7):1001-8. doi: 10.3324/haematol.13012.

6.

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A.

Nat Med. 2010 Jan;16(1):49-58. doi: 10.1038/nm.2054. Epub 2009 Nov 8.

PMID:
19898489
7.

[Myelodysplastic syndrome associated with 5q deletion, review of 3 cases].

Khanfir A, Frikha M, Mseddi S, Elloumi M, Daoud J, Makni F, Amouri A, Gargouri J, Saad A, Souissi T.

Tunis Med. 1997 Mar;75(3):127-31. French. No abstract available.

PMID:
9506035
8.
9.

The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.

Melchert M, Kale V, List A.

Curr Opin Hematol. 2007 Mar;14(2):123-9. Review.

PMID:
17255789
10.

Unusual findings in two patients with acquired deletions of the long arm of chromosome 5 (5q-).

Lishner M, Amato D, Chalvardjian P, Baker MA, Fernandes B, Pantalony D, Dube ID.

Clin Lab Haematol. 1991;13(1):87-92.

PMID:
2060266
11.

The 5q- syndrome: a scientific and clinical update.

Tefferi A, Mathew P, Noël P.

Leuk Lymphoma. 1994 Aug;14(5-6):375-8. Review.

PMID:
7812195
12.

Two karyotypically unrelated clones with the t(5;17) and deletion of 5q in myelodysplastic syndrome.

Novak A, Jankovic G, Rolovic Z.

Cancer Genet Cytogenet. 1992 Aug;62(1):100-2.

PMID:
1521224
13.

Cytogenetic analysis in patients with myelodysplastic syndrome.

Hu N, Bian M.

Proc Chin Acad Med Sci Peking Union Med Coll. 1990;5(3):135-9.

PMID:
2098765
14.

Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.

Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M, Germing U, Royer HD, Royer-Pokora B.

Genes Chromosomes Cancer. 2007 Dec;46(12):1119-28.

PMID:
17823930
15.

Deletion of 5q by t(5;17) in therapy-related myelodysplastic syndrome.

Vandenberghe EA, Mecucci C, Delannoy A, Van den Berghe H.

Cancer Genet Cytogenet. 1990 Aug 1;48(1):49-52. No abstract available.

PMID:
2372787
16.

Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.

Godon C, Talmant P, Garand R, Accart F, Bataille R, Avet-Loiseau H.

Genes Chromosomes Cancer. 2000 Dec;29(4):350-2.

PMID:
11066080
17.

An uncommon case of a child with del(5q) and hypocellular myelodysplastic syndrome.

de Souza DC, Otero L, Tavares Rde C, Dobbin J, Abdelhay E, Fernandez Tde S.

Pediatr Blood Cancer. 2010 Oct;55(4):767. doi: 10.1002/pbc.22633. No abstract available.

PMID:
20589660
18.

Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.

Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP.

Am J Hematol. 2008 Sep;83(9):708-13. doi: 10.1002/ajh.21245.

PMID:
18634051
19.

The 5q- syndrome.

Giagounidis AA, Aul C.

Cancer Treat Res. 2008;142:133-48. Review. No abstract available.

PMID:
18283785
20.

[Parallel loss of c-FMS and GM-CSF genes in myeloid leukemias with 5q-chromosome].

Tanaka K, Takechi M, Shigeta C, Oguma N, Kamada N, Takimoto Y, Kuramoto A, Kyo T, Dohy H.

Rinsho Ketsueki. 1991 Sep;32(9):931-7. Japanese.

PMID:
1942539
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk